A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Trials Related to Ipilimumab
Related studies linked through entity extraction aliases.
BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma
- Status
- WITHDRAWN
- Phase
- PHASE2
IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE2
Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy
- Status
- WITHDRAWN
- Phase
- PHASE1
A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment
- Status
- TERMINATED
- Phase
- PHASE1
IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers
- Status
- COMPLETED
- Phase
- PHASE1
A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma
- Status
- COMPLETED
- Phase
- PHASE1
Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1